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Chemotherapy regimens may have diﬀerential eﬃcacy by histology in nonsmall cell lung cancer (NSCLC). We examined the
impact of histology on survival of patients (N = 2,644) with stage IIIB/IV NSCLC who received ﬁrst-line cisplatin/carboplatin
plus gemcitabine (C/C+G) and cisplatin/carboplatin plus a taxane (C/C+T) identiﬁed retrospectively in the SEER cancer registry
(1997–2002). Patients with squamous and nonsquamous cell carcinoma survived 8.5 months and 8.1 months, respectively
(P = .018). No statistically signiﬁcant diﬀerence was observed in survival between C/C+G and C/C+T in both histologies.
Adjusting for clinical and demographic characteristics, the eﬀect of treatment regimen on survival did not diﬀer by histology
(P for interaction = .257). There was no statistically signiﬁcant diﬀerence in hazard of death by histology in both groups. These
results contrast the predictive role of histology and improved survival outcomes observed for cisplatin-pemetrexed regimens in
advanced nonsquamous NSCLC.
1.Introduction
The American Cancer Society estimates that in 2008 there
were 215,000 new cases of lung cancer and approximately
162,000 lung cancer deaths, making it the leading cause of
cancer mortality in the United States (US) [1]. The most
common form of the disease is non-small cell lung cancer
(NSCLC),whichaccountsforapproximately75%–87% ofall
cases [2, 3]. The estimated 5-year survival rates are: 56% for
stage I, 34% for stage II, 10% for stage III, and 2% for stage
IV [1].
The three most common initial treatments for lung
cancer are surgery, radiation therapy, and chemother-
apy. Chemotherapy used alone is standard treatment for
advanced or metastatic stage NSCLC (i.e., IIIB or IV).
Platinum-based chemotherapy (e.g., cisplatin or carbo-
platin) has improved short-term survival, symptom control,
and health-related quality of life for NSCLC patients in the
last two decades [4–7]. Recent data from pemetrexed trials
have shown that the eﬀect of treatment on survival varied
with histology in patients with advanced NSCLC [8–12].
These studies have investigated the treatment-by-histology
interaction associated with pemetrexed-containing doublets
or pemetrexed monotherapy. A phase III clinical trial in
ﬁrst-line NSCLC showed longer survival with cisplatin-
pemetrexed in patients with nonsquamous cell carcinoma
(HR = 0.81, P = .005) and shorter survival with cisplatin-
pemetrexed in patients with squamous cell carcinoma
(HR = 1.23, P = .05), compared to cisplatin-gemcitabine
[13].AdiﬀerentialeﬀectforpemetrexedaccordingtoNSCLC2 Chemotherapy Research and Practice
histology has also been observed in phase 2 studies in
advanced NSCLC [10, 11]. Several meta-analyses have been
performed to compare cisplatin- and carboplatin-based
chemotherapyinthetreatmentofadvancedNSCLC[14–16].
Results have shown superiority in survival with cisplatin-
basedregimensthatincludedthirdgenerationchemotherapy
and superiority in terms of overall response rate although
cisplatin-based regimens were associated with more severe
toxicities.
Doublet chemotherapy regimens generally consist of a
platinum-based agent (cisplatin or carboplatin) given in
combination with another 3rd-generation cytotoxic com-
pound (e.g., a taxane, gemcitabine, or pemetrexed). In the
event that primary chemotherapy treatment is unsuccessful,
secondary treatments for advanced NSCLC patients may
include pemetrexed, docetaxel, or erlotinib. However, none
of these therapies are curative, and treatment outcome
signiﬁcantly depends on the size, type, and stage of the
tumor and on the patient’s state of health [17]. Median life
expectancy for advanced NSCLC patients in whom one or
more chemotherapy regimens has failed is approximately
fourmonths, during which time only palliative orsupportive
care is given (e.g., pain medication or oxygen) [4].
A study conducted by Ramsey et al. evaluated use,
outcomes,andcostsofalternativetreatmentsamongpatients
with stage IIIB or IV NSCLC [18]. Although the study
provided a useful starting point for studying outcomes
associated with NSCLC, it was based on older data (i.e.,
patients diagnosed between 1994 and 1999), and the role of
histology was not examined in this study. Historically, few
studieshaveexaminedtheimpactofhistologyonsurvivalfor
patients with advanced stage NSCLC, and conclusions have
been inconsistent regarding the prognostic or predictive role
of histology in this population [19].
Recent data from three randomized, controlled phase
III trials of pemetrexed regimens in advanced NSCLC have
prompted a renewed interest in the impact of NSCLC
histology on eﬃcacy outcomes. A retrospective analysis
of trials comparing second-line pemetrexed with doc-
etaxel and a prospective analysis of a trial comparing
ﬁrst-line pemetrexed and cisplatin with gemcitabine and
cisplatin identiﬁed statistically signiﬁcant treatment-by-
histologyinteractions,showingasurvivaladvantagefornon-
squamous cell carcinoma patients treated with pemetrexed
regimens [8, 13]. In addition, a third randomized, placebo-
controlled study investigating maintenance pemetrexed in
advanced NSCLC conﬁrmed the eﬃcacy of pemetrexed
in nonsquamous NSCLC [9]. Given these results and the
lack of studies examining treatment-by-histology interaction
in non-pemetrexed-containing chemotherapy regimens in
patients with advanced NSCLC, the goal of this retrospec-
tive study was to evaluate whether or not histology pre-
dicted NSCLC survival outcomes in patients with advanced
NSCLC with two commonly prescribed ﬁrst-line doublet
combinations, a platinum agent (cisplatin or carboplatin)
plus gemcitabine (C/C+G) and a platinum agent plus a
taxane (docetaxel/paclitaxel) (C/C+T), using data from the
linkedSurveillance,EpidemiologyandEndResultsProgram-
(SEER-) Medicare database.
2. Methods
2.1. Data Source. The present study focused on patients who
were identiﬁed through linked data from the SEER-Medicare
database of the National Cancer Institute and administrative
MedicareclaimsfromtheCentersforMedicareandMedicaid
Services [20]. SEER cancer registry data from 1997 through
2002 were combined with Medicare claims from 1991
through2003fortheanalyses.BecauseMedicareparticipants
are largely aged 65 and older, the sample was limited
to this age group. Twelve registries participated in SEER-
Medicare during 1997–1999 and 16 registries during 2000–
2002, representing 14% and 25% of the US population,
respectively. The combination of SEER and Medicare data
provides information about demographics, comorbidities,
initialcancerdiagnosis,andtreatment,aswellaslonger-term
medical care. The combined dataset facilitates the linking
of stage of diagnosis information with types and lengths of
treatments from time of diagnosis through death [21].
2.2. Sample Selection and Followup. Patients who were newly
diagnosed with stage IIIB/IV NSCLC between 1997 and 2002
wereincludedinthestudy.ThedateofﬁrstNSCLCdiagnosis
in the SEER-Patient Entitlement and Diagnosis Summary
File (PEDSF) was used as the index date for each patient.
Patients were excluded if they were less than 65 years old;
were enrolled in a health maintenance organization (HMO)
at any time from 12 months prior to the index date through
followup; were not eligible for Medicare Part A or B beneﬁts
from 12 months prior to the index date through followup;
had any other cancer diagnosis prior to the index date; had
Medicare eligibility based on end stage renal disease; had
incomplete data (e.g., unknown month of cancer diagnosis);
had a diﬀerence in date of death of 3 months or more as
recorded by SEER and Medicare; or a NSCLC diagnosis date
at death or autopsy. Study patients were followed to evaluate
outcomes from their index date until either death or the
end of the Medicare claims data (i.e., December 31, 2003),
whichever came ﬁrst.
Patients who received C/C+G and C/C+T ﬁrst-line
doublet chemotherapy regimens were included in the sam-
ple. This patient group was chosen because these dou-
blet regimens were the most common ﬁrst-line doublet
chemotherapy regimens in the dataset, received by 84%
of patients on any identiﬁable doublet chemotherapy. The
doublet regimens were identiﬁed from Healthcare Common
Procedure Coding System codes on Medicare claims. The
earliest chemotherapy regimen that occurred during an
initial treatment period (within 30 days prior to and 90
days post-index date), was considered to be the ﬁrst-line
treatment. The 30 days prior to the index date in the
initial treatment period was intended to account for any lag
time in the recording of the NSCLC diagnosis in the SEER
registry. The date of treatment was deﬁned as the date of the
ﬁrst chemotherapy claim, and multiple courses of the same
chemotherapy agent were considered to be part of the ﬁrst-
line treatment. If a second chemotherapy agent was received
within eight days of the ﬁrst agent, then it was considered to
be part of the ﬁrst-line treatment (i.e., doublet regimen).Chemotherapy Research and Practice 3
2.3. Study Measures
2.3.1. Histology. Patients were stratiﬁed by NSCLC histol-
ogy and were further categorized as having squamous or
nonsquamous cell carcinoma. This classiﬁcation was chosen
based on the results of previous studies that demonstrated
survivaladvantagesassociatedwithnonsquamouscellhistol-
ogy compared to squamous cell histology. The squamous cell
carcinoma category included large-cell squamous cancers
and keratinizing and nonkeratinizing squamous cancers
(ICD-0-2 histology codes: 8070/3, 8071/3, 8072/3). The
nonsquamous cell carcinoma category included large cell
nonsquamous cancers, adenocarcinomas, and NSCLCs with
other/mixed histologies (ICD-0-2 histology codes: 8012/3,
8140/3, 8480/3, 8481/3, 8490/3, 8560/3, 8570/3).
2.3.2. Demographic and Clinical Characteristics. The SEER-
Medicare database contained information on gender, race,
geographic region (Midwest, Northeast, South, and West),
location of residence (Metropolitan, Urban, and Rural),
mean household income by zip code, and cancer stage at
diagnosis. The Charlson Comorbidity Index score [22]w a s
calculated from Medicare claims during the 12-month pre-
index period using the Deyo [23] adaptation of the scale for
use with ICD-9-CM diagnosis codes excluding conditions
likely to be related to NSCLC (i.e., chronic lung disease and
malignancy).
2.4. Data Analysis/Statistical Methods
2.4.1. Descriptive Statistics. Patients with stage IIIB/IV
NSCLC were stratiﬁed by histology and described according
to baseline clinical and demographic characteristics.
2.4.2. Survival. Survival was evaluated in terms of months
from the index date until death with patients whose fol-
lowup ended prior to death considered censored. Analyses
comparing survival by histology among patients treated
with C/C+T and C/C+G were conducted both unadjusted
and adjusted for demographic and baseline clinical char-
acteristics. Overall survival was compared by histology
group.Withineachhistologygroup,thesurvivaldistribution
was estimated using the Kaplan-Meier estimator, and the
association between histology and survival was assessed
with the log-rank test. A second analysis that adjusted for
measured confounders using a Cox model was conducted.
In the Cox model analysis, hazard ratios for each covariate
represent the adjusted risk of death among patients with
the covariate compared to patients in the respective referent
categories (females, stage IIIB, non-Hispanic Caucasian,
Charlson Comorbidity Index ≤1, Eastern geographic region,
suburban location of residence, squamous cell carcinoma,
and C/C+G). The model included a term for histology to
assess whether histology was associated with survival and
a treatment-by-histology interaction term to formally test
whether the association between treatment and survival
diﬀered by histology. While used to minimize biases due
to confounding factors, this modeling approach does not
address the potential for confounding due to factors that
were not available to us in the SEER-Medicaid database
and relies on appropriate modeling and other statistical
assumptions [24].
3. Results
From an initial sample of 81,640 patients newly diagnosed
with NSCLC between 1997 and 2002, 31,158 met all
initial study inclusion criteria (Figure 1). Approximately
34% (n = 10,475) were diagnosed at Stage IV, and 18%
(n = 5,598) were diagnosed at Stage IIIB. Of these, 5,410
patientsreceivedﬁrst-linechemotherapy,4,230ofwhomhad
recordsallowingforidentiﬁcationofaspeciﬁcchemotherapy
regimen, and 3,130 of whom received a doublet regimen.
Of these, 2,644 patients received C/C+T or C/C+G. This
last group comprised the ﬁnal analytic sample (Figure 1).
Descriptive statistics for the baseline patient characteristics
stratiﬁed by histology are shown in Table 1. The mean age
of the stage IIIB/IV patients was 73 years old, collapsing
across histology. A majority of patients were male (68.7%
in the squamous cell carcinoma group and 55.5% in the
nonsquamous cell carcinoma group) and most were non-
HispanicCaucasians,(90.4%inthesquamouscellcarcinoma
group and 91.0% in the nonsquamous cell carcinoma
group). A greater number of patients lived in the western
region of the US (31.8% in the squamous cell carcinoma
groupand40.2% inthe nonsquamouscellcarcinomagroup)
compared to the three other geographic regions, and most
patients lived in a metropolitan area (85.2% collapsing
across histology). The mean Charlson Comorbidity Index
score excluding chronic obstructive pulmonary disease and
cancer was 0.19 ± 0.6 in the squamous cell carcinoma
group and 0.18 ± 0.5 in the nonsquamous cell carcinoma
group.
Figures 2 and 3 present Kaplan-Meier curves comparing
survival among patients receiving C/C+T and C/C+G by
histology. No signiﬁcant diﬀerence in survival between ther-
apies was found in either the nonsquamous cell carcinoma
group or squamous group. Figures 4 and 5 present the
Kaplan-Meier curves comparing survival between histology
groupsamongpatientsreceivingC/C+TandC/C+G,respec-
tively. Overall, median survival of patients with squamous
cell carcinoma was higher than for patients with nonsqua-
mous cell carcinoma (8.5 months and 8.1 months, resp.;
P = .018). Among patients receiving C/C+T, the median
survival was 8.6 months and 8.2 months for patients with
squamous cell carcinoma and nonsquamous cell carcinoma,
respectively (P = .009). Among patients receiving C/C+G,
the median survival was 8.2 months and 8.1 month for
squamous cell carcinoma and nonsquamous cell carcinoma,
respectively (P = .601).
Table 2 shows the Cox proportional hazard ratios for
the characteristics associated with death for patients who
receivedC/C+GandC/C+Tasﬁrst-linetreatment.Increased
risk of death was observed for older age (HR = 1.009, 95%
CI = 1.001–1.018 for each additional year), male sex (HR
= 1.31, 95% CI 1.21–1.42), and stage IV (HR = 1.38, 95%
CI 1.27–1.49). Increased risk of death was observed for4 Chemotherapy Research and Practice
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sample size
(N = 81,640)
Exclusion criteria:
(1) Aged ≤ 65 at diagnosis
(2) History of other cancer prior to NSCLC diagnosis
(3) Stage 0 or unknown at diagnosis
(4) Gap in Part A or B Medicare coverage in 12 months prior to index through follow-up
(5) Medicare HMO enrollment in 12 months prior to or during study period
(6) Medicare eligibility on basis of disability or ESRD
(7) Date of death diﬀered by > 3 months between SEER and Medicare databases
(8) NSCLC diagnosis at death or autopsy
Remaining sample
N = 69,821
N = 59,310
N = 55,322
N = 49,817
N = 35,084
N = 31,216
N = 31,216
N = 31,158
Newly diagnosed NSCLC 1997–2002
(N = 31,158)
Diagnosed with stage IIIB/IV
(N = 16,073)
All stage IIIB/IV patients treated with
ﬁrst-line chemotherapy (N = 5,410)
Stage IIIB/IV patients treated with
identiﬁable ﬁrst-line chemotherapy
(N = 4,230)
Stage IIIB/IV patients treated with identiﬁable ﬁrst-line
doublet chemotherapy (N = 3,130)
Stage IIIB/IV patients treated with C/C+T or C/C+G
(N = 2,644)
Notes: C/C+G: cisplatin/carboplatin and gemcitabine, C/C+T: cisplatin/carboplatin and taxane;
ESRD: end-stage renal disease; HMO: health maintenance organization; NSCLC: non-small
cell lung cancer; SEER: surveillance, epidemiology, and end results.
Figure 1: Flow of patients with Stage IIIB/IV who received cisplatin/carboplatin plus taxane (C/C+T) or cisplatin/carboplatin plus
gemcitabine (C/C+G) ﬁrst-line doublet chemotherapy from identiﬁcation to sample selection.
nonsquamous cell histology (HR = 1.14, 95% CI 1.03–1.25).
Survival did not diﬀer by treatment regimen (P = .29),
nor did treatment regimen aﬀect the association between
histology and survival (P = .26). Thus, while C/C+T in
squamous patients had longer median survival than C/C+G
by histology type combinations, there was no suﬃcient
evidence in this sample to declare a statistically signiﬁcant
interaction.
4. Discussion
The present study examined the relationship between his-
tology and survival in patients 65 years of age and older
with stage IIIB/IV NSCLC receiving doublet chemotherapy
regimens. Combining SEER and Medicare data provides
information on both initial cancer diagnosis and later cancer
treatment. SEER-Medicare data have been used in severalChemotherapy Research and Practice 5
Table 1:Baselinecharacteristicsfor2,644patientswithstageIIIB/IVNSCLCtreatedwithC/C+GorC/C+T,ﬁrst-linedoubletchemotherapy,
by histology, SEER-Medicare Data 1997–2003.
Histology
Squamous Nonquamous
Characteristic
Patients, n (%) 757 (28.6) 1,887 (71.4)
Doublet, n (%)
C/C+G 84 (11.1) 289 (15.4)
C/C+T 673 (88.9) 1,598 (84.7)
A g ea so fi n i t i a lN S C L Cd i a g n o s i s :
Mean (SD) 73 (4.6) 73 (4.7)
Median 72 73
Interquartile range 69–76 69–76
Age-group as of initial NSCLC diagnosis, n (%)
65–74 years 507 (67.0) 1,196 (63.4)
75+ years 250 (33.30) 691 (36.6)
Male, n (%) 520 (68.7) 1,047 (55.5)
Race, n (%)
Non-Hispanic Caucasian 684 (90.4) 1,718 (91.0)
Other 73 (9.6) 169 (9.0)
Geographic region, n (%)
Midwest 169 (22.3) 345 (18.3)
Northeast 157 (20.8) 393 (20.8)
South 190 (25.1) 391 (20.7)
West 241 (31.8) 758 (40.2)
Location of residence, n (%)
Metropolitan 628 (83.0) 1.626 (86.2)
Other 129 (17.0) 261 (13.8)
Charlson comorbidity index, mean (sd) 0.19 (0.57) 0.18 (0.52)
Notes: C/C+G: cisplatin/carboplatin and gemcitabine; C/C+T: cisplatin/carboplatin and taxane; NSCLC: non-small cell lung cancer; SD: standard deviation;
SEER: surveillance, epidemiology, and end results.
published studies of a variety of cancers, including cancers
of the breast, prostate, lung, and colon [20]. The combined
source is appealing for cancer studies due to its size,
comprehensiveness, and accessibility.
The median survival associated with the use of C/C+G
and C/C+T in our study was lower than what has been
observed in clinical trials [12, 25]. We speculate that such
diﬀerences may be explained threefold. First, the mean age of
participants in our study was 73 years compared to a range
of 62–64 years observed in most clinical trials not restricted
to an older population; second, due to data limitations,
we were unable to stratify or exclude patients based on
k e yb a s e l i n ec h a r a c t e r i s t i c ss u c ha sp e r f o r m a n c es t a t u s( P S ) ,
organ function, or comorbidities; third, patients included in
this investigation may not have had the same strict followup
as dictated in controlled clinical trials.
To our knowledge, this is the ﬁrst study that examined
treatment-by-histology interaction in nonpemetrexed-
containing chemotherapy regimens for patients with
advanced stage NSCLC. A systematic review of the published
literature has shown that very few studies in advanced
NSCLC have examined a formal treatment-by-histology
interaction test [19]. Our study, which included a formal
test of histology interaction, suggested that histology did not
predict any signiﬁcant diﬀerences in survival with C/C+G
or C/C+T regimens, such that no survival advantages were
identiﬁed for these regimens in either histology subgroup.
We did observe a slightly increased risk of death associated
with nonsquamous cell histology both overall and with
patients treated with C/C+T. However, the generalizability
of these results is limited to patients aged 65 years and older
with advanced NSCLC receiving C/C+G or C/C+T.
This study is not without limitations. First, we partially
relied on administrative Medicare claims data for patients
aged 65 years and older. Medicare claims are primarily used
for administrative purposes in obtaining reimbursement for
services and not for research purposes. SEER data are limited
intheamountofclinicalandbaselineinformation;therefore,
we were unable to examine prognostic variables such as
weight loss, smoking status, and PS as well as to evaluate
the impact of the treatment on quality of life. Furthermore,
patients enrolled in other forms of coverage than Medicare
were excluded from the analyses. To the extent that patients
aged less than 65 years may receive diﬀerent treatments than6 Chemotherapy Research and Practice
Table 2: Characteristics associated with death following diagnosis of NSCLC, stage IIIB/IV for patients receiving C/C+G or C/C+T ﬁrst-line
chemotherapy.
Characteristics N = 2,644 95% CI
Hazard ratio Lower limit Upper limit P
Age at diagnosis 1.009 1.001 1.018 .0339
Sex
Male 1.310 1.207 1.422 <.0001
Female 1.00 (Referent)
Stage at diagnosis
IV 1.376 1.266 1.495 <.0001
IIIB 1.00 (Referent)
Race
Non-Hispanic Caucasian 1.069 0.932 1.226 0.3374
Other 1.00 (Referent)
Comorbidity
Charlson > 1 1.204 0.991 1.464 0.0617
Charlson ≤ 1 1.00 (Referent)
SEER registry region
Northeast 0.999 0.897 1.113 0.9878
Midwest 1.044 0.935 1.166 0.4467
South 1.036 0.930 1.153 0.5253
West 1.00 (Referent)
Location of residence
Metro 1.001 0.893 1.121 0.9916
Other 1.00 (Referent)
Histology
Nonsquamous cell 1.138 1.034 1.251 0.0079
Squamous cell 1.00 (Referent)
Primary treatment
C/C+G 1.137 0.900 1.436 0.2825
C/C+T 1.00 (Referent)
Histology∗treatment interaction
Nonsquamous∗C/C+G 0.857 0.656 1.119 0.2561
Notes: C/C+G: cisplatin/carboplatin and gemcitabine, C/C+T: cisplatin/carboplatin and taxane.
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Figure 2: Kaplan-Meier survival curve of patients on doublet
chemotherapy, by treatment, stage IIIB/IV, squamous.
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Figure 3: Kaplan-Meier survival curve of patients on doublet
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Figure 5: Kaplan-Meier survival curve of patients on doublet
chemotherapy, by histology, stage IIIB/IV, C/C+G.
older patients, our results may not be applicable to younger
NSCLC patients. SEER-Medicare data are subject to some
additional limitations, including that patients from SEER
registries may not be representative of all US patients with
NSCLC and certain groups are under- or over-represented
(e.g., African-Americans and “other” races, resp., [8, 9]).
Also, the algorithm developed to identify ﬁrst-line therapy
considered any chemotherapy administration that occurred
within 8 days of the ﬁrst drug to be a component of ﬁrst-line
treatment. Therefore, such algorithm increases the chances
of missing those regimens given on a 21-day schedule, as well
as those patients who experienced dose delays. Small sample
sizes in certain histological subgroups precluded further
separation of histology subgroups. As in any retrospective
analysis, it is important to keep in mind that we are
reporting claims data which is subject to errors in coding
of diagnoses and procedures. Lastly, caution must be taken
when interpreting comparative results from such naturalistic
data as one cannot be certain that all confounding factors
such as smoking history and PS have been accounted for.
Additionaldatatotestthereplicationoftheseﬁndingswould
be of great value.
Our ﬁndings provide increased understanding of sur-
vival among patients with stage IIIB/IV NSCLC, highlight-
ing the role of histology in relationship to survival and
chemotherapy. Median survival was longer for patients with
squamous cell histology relative to the nonsquamous group.
Whereas the C/C+T chemotherapy did have numerically
longer median survival than the C/C+G in patients with
squamous histology, the unadjusted Kaplan-Meier analysis
directly comparing therapies within the squamous patients
was nonsigniﬁcant. In addition, in the Cox model, the
lack of a signiﬁcant treatment eﬀect and the lack of a
signiﬁcant treatment by histology interact suggest that there
is not enough evidence in this sample to claim a diﬀerential
treatment eﬀect overall or between the histology groups.
The lack of strong evidence showing diﬀerential treatment
eﬀects for C/C+T versus C/C+G in either histology group
contrasts the results of clinical trials in patients treated with
pemetrexed-containing regimens. These ﬁndings suggest
that histology should be considered in the selection of
treatment for patients with advanced NSCLC, particularly in
regimens containing pemetrexed. Further studies are needed
to conﬁrm these ﬁndings.
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